Publications
Detailed Information
Dynamics of soluble programmed death-ligand 1 (SPDL1) during chemotherapy and its prognostic implications in cancer patients: Biomarker development in immuno-oncology
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ha, Hyerim | - |
dc.contributor.author | Bang, Ju-Hee | - |
dc.contributor.author | Nam, Ah-Rong | - |
dc.contributor.author | Park, Ji-Eun | - |
dc.contributor.author | Jin, Mei Hua | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.date.accessioned | 2021-01-31T11:58:56Z | - |
dc.date.available | 2021-01-31T11:58:56Z | - |
dc.date.created | 2019-09-05 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.citation | Cancer Research and Treatment, Vol.51 No.2, pp.832-840 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.other | 82863 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173181 | - |
dc.description.abstract | Purpose The soluble programmed death-ligand 1 (sPDL1) has immunosuppressive activity and is a candidate biomarker for immuno-oncology drug development. In this study, we measured sPDL1 at pre-and post-chemotherapy and at disease progression to uncover the dynamics of sPDL1 during treatment in biliary tract cancer (BTC) patients. Materials and Methods From 90 BTC patients (training cohort, 53; validation cohort, 37) who were candidates for palliative first-line chemotherapy, blood was collected at pre-and post-chemotherapy (at the time of best response) and at disease progression. The sPDL1 levels were measured using an enzyme-linked immunosorbent assay. Responses to chemotherapy, overall survival (OS), and other prognostic factors including the neutrophil-lymphocyte ratio (NLR) were analyzed. Results The OS of all patients was 11.5 months (confidence interval [CI], 9.7 to 16.2). The best response was complete response in seven (7.8%), partial response in 20 (22.2%), stable disease in 52 (57.8%), and disease progression (PD) in 11 patients (12.2%). Patients with high pre-chemotherapy sPDL1 (>= 1.30 ng/mL) showed worse OS than patients with low prechemotherapy sPDL1 (9.1 months vs. 12.5 months, p=0.003). In multivariate analyses, high pre-chemotherapy sPDL1 (hazard ratio [HR], 1.96; 95% CI, 1.2 to 3.9; p=0.011) and high pre-chemotherapy NLR (HR, 1.82; 95% CI, 1.1 to 3.0; p=0.020) were independent poor prognostic factors for OS. At the time of PD, sPDL1 was increased significantly compared with pre-chemotherapy sPDL1 (1.59 ng/mL vs. 0.72 ng/mL, p=0.003). Conclusion The sPDL1 at pre-chemotherapy confers the prognostic value for OS in BTC patients under palliative chemotherapy. The dynamics of sPDL1 during chemotherapy correlate with disease burden and have prognostic value. | - |
dc.language | 영어 | - |
dc.publisher | 대한암학회 | - |
dc.title | Dynamics of soluble programmed death-ligand 1 (SPDL1) during chemotherapy and its prognostic implications in cancer patients: Biomarker development in immuno-oncology | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.4143/crt.2018.311 | - |
dc.citation.journaltitle | Cancer Research and Treatment | - |
dc.identifier.wosid | 000464009400041 | - |
dc.identifier.scopusid | 2-s2.0-85064494674 | - |
dc.citation.endpage | 840 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 832 | - |
dc.citation.volume | 51 | - |
dc.identifier.sci | 000464009400041 | - |
dc.identifier.kciid | ART002456223 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CLINICAL-SIGNIFICANCE | - |
dc.subject.keywordPlus | CELL | - |
dc.subject.keywordPlus | PD-L1 | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | BLOCKADE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | B7-H1 | - |
dc.subject.keywordAuthor | Soluble PDL1 | - |
dc.subject.keywordAuthor | PDL1 | - |
dc.subject.keywordAuthor | Dynamics | - |
dc.subject.keywordAuthor | Biomarkers | - |
dc.subject.keywordAuthor | Prognosis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.